Research Paper Volume 14, Issue 3 pp 1492—1507
Identification and validation of a twelve immune infiltration-related lncRNA prognostic signature for bladder cancer
Figure 7. Prediction of the sensitivity of high risk patients to chemotherapy drugs and immunotherapy. (A) Cisplatin. (B) Doxorubicin. (C) Methotrexate. (D) Gemcitabine. (E) Vinblastine. (F) Immune checkpoint receptor: PD1-R, PD1-noR, CTLA4-R, ctal4-noR.